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Law, history and lessons in the CRISPR patent conflict
Jacob S Sherkow
Predicting the outcome of the ongoing patent disputes surrounding genome-editing technology is equal parts  
patent analysis and history.
Genome-editing technology based on clustered, regularly interspaced, short 
palindromic repeats (CRISPR) and CRISPR-
associated protein 9 (Cas9) has generated great 
excitement in both academia and industry. But 
a potential patent dispute between two sets of 
inventors has left the biotech community pon-
dering its fate. Understanding several facets of 
patent law and history may provide some les-
sons about the probable—and best—outcome 
for the dispute.
CRISPR and the patent landscape
The CRISPR-Cas9 genome-editing system is 
based on an endogenous, prokaryotic immune 
response to foreign nucleic acids, such as viral 
genomes or plasmids. When presented with 
viruses or plasmids, some prokaryotes inte-
grate short fragments of the foreign sequence 
into one or more CRISPR loci, and then tran-
scribe the loci and process the output to form 
short CRISPR RNAs (crRNAs). The newly cre-
ated crRNAs then direct Cas9, a DNA nucle-
ase, to cleave future foreign nucleic acids on the 
basis of sequence complementarity. The sys-
tem’s ability to precisely introduce foreign DNA 
sequences makes CRISPR-Cas9 an incredibly 
versatile, effective system for genomic editing.
That versatility, and the potential to use 
CRISPR-Cas9 for practical (and profitable) 
in vivo applications, has led to two competing 
patent claims on the CRISPR-Cas9 system. The 
first stems from work led by Jennifer Doudna, 
at the University of California, Berkeley (UC 
Berkeley), and Emmanuelle Charpentier, at 
the Helmholtz Centre for Infection Research 
in Germany, for a method of exploiting the 
system for genome editing in vitro1. Their 
patent application, which claims a priority date 
of May 25, 2012, includes 155 claims, encom-
passing numerous applications of the system 
for a variety of cell types2. The second comes 
from Feng Zhang of MIT on a method for using 
CRISPR-Cas9 for genome editing in eukaryotic 
cells3. Zhang’s patent, which claims a priority 
date of December 12, 2012, has already been 
issued4.
Since these filings, there has been a flurry 
of patent applications related to CRISPR-Cas9. 
More than a dozen new patents and 100 patent 
applications have claimed or described appli-
cations for the CRISPR-Cas9 system. Zhang 
alone has received eight CRISPR-Cas9 patents, 
all from ‘fast-tracked’ applications and drafted 
to very broad applications of the technology. 
Some of these patents are directed to more spe-
cific applications, such as the patent claiming 
the use of the technology to treat Huntington’s 
disease5.
Challenges to the patents
The breadth and competing claims of these 
patents and patent applications pose several 
challenges to their inventors—and to the 
biotech community at large. The first con-
cerns the priority of the fomenting patent 
dispute between Doudna and Charpentier, on 
one side, and Zhang on the other. Currently, 
the patent application from Doudna and 
Charpentier appears to have priority over 
Zhang’s earliest issued patent—theirs claims a 
priority date of May 25, 2012, whereas Zhang’s 
claims a priority date of December 12, 2012. 
Assuming Zhang’s claims overlap with those 
of Doudna and Charpentier, this may allow 
the Doudna-Charpentier team to petition the 
US Patent and Trademark Office (USPTO) to 
challenge Zhang’s initial patent through an 
“interference proceeding” if their application 
is ultimately rejected6. The stakes for an inter-
ference proceeding would be high: if Doudna 
and Charpentier were to win, Zhang’s earliest 
patent would be invalidated, although there 
would be no guarantee that the Doudna-
Charpentier patent application would be 
granted. If Zhang were to win, he would keep 
his initial patent, and Doudna and Charpentier 
would likely walk away empty handed.
The second challenge concerns the patents’ 
scope. All of the CRISPR patent applications 
filed thus far are drafted quite broadly. As a 
consequence, if the USPTO allows these pat-
ent applications to move forward—and if the 
patents are ultimately enforced—the patents 
are likely to prevent even the most basic use 
of the CRISPR-Cas9 system without a license. 
General academic research would almost cer-
tainly be liable for patent infringement7. At 
the same time, the patent statute immunizes 
research performed in connection with sub-
mitting new drug or biologic information to 
the US Food and Drug Administration8. Thus, 
depending on the enforcement scheme and the 
technology’s development, academic research 
may be subject to claims of patent infringement 
while some commercial development may pro-
ceed unchecked.
Last, the patents themselves pose sev-
eral questions concerning their validity. 
Specifically, patent claims that are “obvious” 
may be declared “invalid” and may be freely 
used by others9. In the biotechnology context, 
there has been a long-running and unresolved 
issue about whether certain applications of a 
technology are obvious once the fundamentals 
of a technology (such as PCR) are known. Now 
that the mechanics of CRISPR-Cas9 are known, 
have genome-editing applications become 
obvious? Answering that question in legal 
terms is immensely difficult, but the answer is 
likely to control the future of all CRISPR-Cas9 
patent disputes.
Historical precedents
Whether and how these difficulties are 
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Conclusion
CRISPR-Cas9 is a very promising tool in the 
quest for genome editing. Whether the tech-
nology is allowed to develop with patent pro-
tection will be up to law and history, rather 
than science.
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versity currently allows academic scientists 
with laboratory-made versions of the molecu-
lar components to use the technology for free 
and grants companies selling these molecu-
lar components nonexclusive licenses11. The 
startup Alnylam, however, has received an 
exclusive license to the technology for thera-
peutic applications.
The PCR patents provide another option 
for licensing and deployment. Because the 
technology was discovered in the context of 
industry, strong enforcement of PCR patents 
could have significantly hindered scientific 
progress. This problem was largely miti-
gated, however, through the twin policies of 
‘rational forbearance’ from suing research-
ers for patent infringement and the adoption 
of widespread corporate licensing, business 
partnerships and adaptive licensing strate-
gies12. In this way, PCR was widely—and 
quickly—disseminated.
Although these examples are quite different 
from one another, in all cases, the assignees 
chose an appropriate and user-specific combi-
nation of enforcement and licensing. Choosing 
the right strategy or strategies may help the 
CRISPR-Cas9 patent assignees to avert legal 
challenges, realize significant revenue streams 
and promote scientific progress simultaneously.
the dueling patent applications: UC Berkeley, 
the University of Vienna, the Massachusetts 
Institute of Technology (MIT) and the Broad 
Institute. The history of licensing patents 
on earlier foundational technologies— 
recombinant DNA, small interfering RNA 
(siRNA) and PCR—provide several avenues 
for deploying CRISPR-Cas9 without lengthy 
patent fights. Stanford University’s manage-
ment of the Cohen-Boyer patents on recombi-
nant DNA, for example, has become the gold 
standard for university technology licens-
ing10. First, the patents’ assignee, Stanford, 
licensed the technology nonexclusively and 
allowed nonprofit research institutions to 
use the technology without a license. Second, 
the university developed a graduated royalty 
system to ensure that smaller companies were 
not disadvantaged. And finally, Stanford pre-
emptively consulted a wide variety of stake-
holders and experimented with different 
licensing agreements, to much community 
fanfare.
Another helpful example to consider is 
MIT’s ‘Tuschl patents’ on siRNA technol-
ogy. As with CRISPR-Cas9, overly restric-
tive licensing could have significantly slowed 
scientific progress. MIT, however, was able to 
avert this problem through licensing. The uni-
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